SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors

NCT05387044 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

28

Enrollment

OTHER

Sponsor class

Conditions

NSCLC Stage IV

Interventions

RADIATION: SBRT

Sponsor

Zhejiang Cancer Hospital